Territory Stories

NT trends in ecstasy and related drug markets 2011 : findings from the Ecstasy and Related Drugs Reporting System (EDRS)

Details:

Title

NT trends in ecstasy and related drug markets 2011 : findings from the Ecstasy and Related Drugs Reporting System (EDRS)

Collection

NT trends in ecstasy and related drug markets; Reports; PublicationNT

Date

2011

Description

Made available via the Publications (Legal Deposit) Act 2004 (NT).

Notes

Date:2011; Australian drug trends series No. 80

Language

English

Subject

Drug abuse surveys -- Northern Territory -- Periodicals; Ecstasy (Drug) -- Northern Territory -- Periodicals; Drug abuse -- Northern Territory -- Periodicals

Publisher name

National Drug and Alcohol Research Centre, University of New South Wales

Place of publication

Sydney (N.S.W)

ISBN

9780733430206

Copyright owner

Check within Publication or with content Publisher.

Parent handle

https://hdl.handle.net/10070/242182

Citation address

https://hdl.handle.net/10070/610318

Page content

64 Table 52: Overdose on other drugs by participants, 2007-2011 (%) Drug 2007 N=106 2008 N=103 2009 N=99 2010 N=99 2011 N=98 LSD 0 1 0 0 0 Ecstasy 2 1 1 0 0 Benzodiazepines 8 7 5 5 4 Alcohol 8 2 1 1 0 Cannabis 1 1 0 0 0 Speed 8 2 2 0 0 Base 0 1 0 0 0 Ice/crystal 0 0 0 0 0 Antidepressants 0 0 0 0 0 Pharmaceutical stimulants 0 0 0 0 0 Morphine 0 5 5 1 2 Other opiates 0 0 1 2 2 Inhalants 0 0 1 0 0 Source: IDRS participant interviews 6.1.3 KE comment In 2011, no KE commented specifically upon overdoses and drug-related fatalities, with comments falling under the more general heading of Injecting Risk Behaviours. 6.2 Drug treatment In 2011, only 4% of participants reported current attendance at treatment compared to 12% in 2010. In 2011, treatment was comprised of methadone/biodone (1%), detoxification (1%), Subutex (1%) and Suboxone (1%). The proportion of participants reporting treatment in the last six months was roughly equivalent to that reported in 2010 and remained low (Figure 36). Suboxone treatment (by 5% of participants) was the most common form of treatment reported in the past six months. As discussed in the 2010 IDRS report, the Opiate Pharmacotherapy Program is provided by the NT Department of Healths Tobacco, Alcohol and Other Drugs Program. Suboxone is the first line of opiate substitution treatment and methadone (Biodone) is provided to interstate transfers who had previously commenced on methadone, pregnant clients or those who have exhibited a notifiable reaction to Suboxone.


Aboriginal and Torres Strait Islander people are advised that this website may contain the names, voices and images of people who have died, as well as other culturally sensitive content. Please be aware that some collection items may use outdated phrases or words which reflect the attitude of the creator at the time, and are now considered offensive.

We use temporary cookies on this site to provide functionality.
By continuing to use this site without changing your settings, you consent to our use of cookies.